You commented previously that you don't talk with CVBT because you prefer 3rd party information sources such as the FDA, SEC and tthe rest. That is fine for public entities however for private companies the main source is the company itself.
I bought into the $3 offering. I met the CEO in Singapore earlier this year. A good straightforward guy and the largest shareholder in CVBT. I originally purchased CVBT on the OTCBB years ago and had an average price of just over 30 cents per share. I subscribed for a further 33,334 shares a couple of months ago. I have to correct your negative worth assertion. CVBT has reorganised the balance sheet by drastically smashing the debt onboard. The progress on the patent portfolio is impressive. IP is what drives value in biotech.
Market Data 
Markets 
AI
